MedTrace Logo

Impact of Curcumin and Pentoxiphylline on Chronic Kidney Disease Patients

NCT06458465 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-05-28

No results posted yet for this study

Summary

The aim of the study is to evaluate the impact of turmeric and pentoxiphylline on serum levels of protein-bound uremic toxin (p-cresyl sulfate), oxidative stress biomarker level (Malonaldehyde), inflammatory biomarker level (Highly sensitive C-reactive protein). In addition to the evaluation of its effect on metabolic profile and disease progression in chronic kidney disease patients.

Conditions

Interventions

DIETARY_SUPPLEMENT

Curcumin

\- Curcumin capsules 500 mg twice daily for 6 months

DRUG

Pentoxifylline 400 MG

\- Pentoxifylline 400 mg twice daily for 6 months.

Sponsors & Collaborators

  • Tanta University

    collaborator OTHER

  • Alexandria University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2024-09-01
Completion
2024-10-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06458465 on ClinicalTrials.gov